homovanillic acid has been researched along with Anochlesia in 65 studies
Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.
homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.
homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, in contrast to D2-selective antagonists, SCH39166 failed to increase plasma prolactin levels, did not block apomorphine-induced emesis in the dog and had minimal effects on the striatal levels of homovanillic acid or dihydroxyphenylacetic acid." | 3.67 | Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity. ( Barnett, A; Berger, JG; Chipkin, RE; Coffin, VL; Iorio, LC; McQuade, RD, 1988) |
| "Chronic administration of the same dose of cocaine to rhesus monkeys for up to 6 months was associated with progressive alterations in pathological behavior and increased susceptibility to seizures." | 3.65 | Progressive effects of cocaine on behavior and central amine metabolism in rhesus monkeys: relationship to kindling and psychosis. ( Black, KE; Kopanda, RT; Post, RM, 1976) |
| "Behaviour was evaluated by catalepsy tests and activity box." | 1.32 | Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. ( Schmidt, WJ; Srinivasan, J, 2003) |
| "Dopaminergic lesion produced catalepsy and hypoactivity." | 1.32 | Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease. ( Schmidt, WJ; Srinivasan, J, 2004) |
| "Haloperidol-treated rats showed an increase of DA, DOPAC, and HVA overflow in the PFC and the NAC-C." | 1.29 | Dopamine increase in the prefrontal cortex correlates with reversal of haloperidol-induced catalepsy in rats. ( Baptista, T; Fernandez, R; Hernandez, L; Murzi, E; Tucci, S, 1994) |
| "Nicotine potentiated the catalepsy produced by haloperidol." | 1.29 | Nicotine potentiation of haloperidol-induced catalepsy: striatal mechanisms. ( Cahill, DW; el-Etri, MM; Emerich, DF; Norman, AB; Sanberg, PR; Shipley, MT; Zanol, MD, 1993) |
| "4." | 1.29 | Prevention by (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol. ( Andersen, HL; Kilpatrick, IC, 1996) |
| "The catalepsy was significantly decreased by IP atropine." | 1.28 | Catalepsy induced by striatal acetylcholinesterase inhibition with fasciculin in rats. ( Bolioli, B; Castelló, ME; Dajas, F, 1992) |
| "Homovanillic acid was measured in the striatum and the prefrontal cortex on the 2nd day." | 1.28 | The enhancement of the hypomotility induced by small doses of haloperidol in the phase of dopaminergic supersensitivity in mice. ( Abe, E; Fujiwara, H; Itoh, T; Kohori, I; Masuda, Y; Murai, S; Saito, H, 1991) |
| "All rats were tested for catalepsy and at the end of the last catalepsy test, striatal DOPAC, HVA and ACh were determined." | 1.27 | Conditional tolerance to haloperidol-induced catalepsy is not caused by striatal dopamine receptor supersensitivity. ( de Graaf, CJ; Korf, J, 1986) |
| "At their ED50S on catalepsy, the neuroleptics evoked HVA changes which varied according to the drug tested." | 1.26 | A comparison between some biochemical and behavioural effects produced by neuroleptics. ( Fregnan, GB; Porta, R, 1981) |
| "Gabaculine also induced catalepsy of medium intensity and potentiated the effect of haloperidol 24h after injection, when GABA was increased in the globus pallidus as well as in the substantia nigra." | 1.26 | Cataleptic and anticataleptic effects of muscimol and gabaculine injected into globus pallidus and substantia nigra, and interactions with haloperidol or benzodiazepines. ( Kamioka, T; Matsui, Y, 1978) |
| "Concomitant with the onset of catalepsy there is a rise in HVA and DOPAC concentrations in whole and discrete parts of the brain (striatum, limbic system)." | 1.26 | Role of the dopaminergic system in the cataleptogenic action of bulbocapnine. ( Longo, VG; Massotti, M, 1979) |
| "Mecamylamine pretreatment reduced the morphine- and haloperidol-induced elevation of striatal HVA concentrations." | 1.26 | Effect of mecamylamine on the fate of dopamine in striatal and mesolimbic areas of rat brain; interaction with morphine and haloperidol. ( Ahtee, L; Kaakkola, S, 1978) |
| "The time courses of the catalepsy and the reduction in brain monoamines were very similar." | 1.26 | Production of catalepsy and depletion of brain monoamines by a butyrophenone derivative. ( Fuenmayor, LD; Vogt, M, 1979) |
| "The combination quickly caused a strong catalepsy." | 1.25 | On a prime role for newly synthesized dopamine in striatal function. ( Dorris, RL; Shore, PA, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 46 (70.77) | 18.7374 |
| 1990's | 10 (15.38) | 18.2507 |
| 2000's | 6 (9.23) | 29.6817 |
| 2010's | 3 (4.62) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Celorrio, M | 1 |
| Rojo-Bustamante, E | 1 |
| Fernández-Suárez, D | 1 |
| Sáez, E | 1 |
| Estella-Hermoso de Mendoza, A | 1 |
| Müller, CE | 1 |
| Ramírez, MJ | 1 |
| Oyarzábal, J | 1 |
| Franco, R | 1 |
| Aymerich, MS | 1 |
| Aguiar, AS | 1 |
| Lopes, SC | 1 |
| Tristão, FS | 1 |
| Rial, D | 1 |
| de Oliveira, G | 1 |
| da Cunha, C | 1 |
| Raisman-Vozari, R | 1 |
| Prediger, RD | 1 |
| Gołembiowska, K | 1 |
| Dziubina, A | 1 |
| Kowalska, M | 1 |
| Kamińska, K | 1 |
| Batool, F | 1 |
| Shah, AH | 1 |
| Ahmed, SD | 1 |
| Saify, ZS | 1 |
| Haleem, DJ | 1 |
| Srinivasan, J | 2 |
| Schmidt, WJ | 2 |
| Zetterström, T | 1 |
| Sharp, T | 1 |
| Ungerstedt, U | 1 |
| Georgiev, VP | 1 |
| Klousha, VE | 1 |
| Petkov, VD | 1 |
| Markovska, VL | 1 |
| Svirskis, SV | 1 |
| Mountsinietse, RK | 1 |
| Anouans, ZE | 1 |
| Fregnan, GB | 1 |
| Porta, R | 1 |
| Allikmets, LH | 1 |
| Zarkovsky, AM | 1 |
| Nurk, AM | 1 |
| Arribas, E | 1 |
| Vega, S | 1 |
| Benito, C | 1 |
| Fernandez-Tome, MP | 1 |
| del Rio, J | 1 |
| Xu, J | 1 |
| Jin, GZ | 1 |
| Yu, LP | 1 |
| Liu, XJ | 1 |
| Naik, SR | 1 |
| Kelkar, MR | 1 |
| Amladi, SR | 1 |
| Sheth, UK | 1 |
| Bowers, MB | 1 |
| Rozitis, A | 1 |
| Tucci, S | 1 |
| Fernandez, R | 1 |
| Baptista, T | 1 |
| Murzi, E | 1 |
| Hernandez, L | 1 |
| Sanberg, PR | 1 |
| Emerich, DF | 1 |
| el-Etri, MM | 1 |
| Shipley, MT | 1 |
| Zanol, MD | 1 |
| Cahill, DW | 1 |
| Norman, AB | 1 |
| Andersen, HL | 1 |
| Kilpatrick, IC | 2 |
| Horikawa, HP | 1 |
| Nakazato, T | 1 |
| Hikosaka, O | 1 |
| Mohanakumar, KP | 1 |
| Muralikrishnan, D | 1 |
| Thomas, B | 1 |
| Antkiewicz-Michaluk, L | 1 |
| Michaluk, J | 1 |
| Romańska, I | 1 |
| Papla, I | 1 |
| Vetulani, J | 1 |
| Campiani, G | 1 |
| Butini, S | 1 |
| Gemma, S | 1 |
| Nacci, V | 1 |
| Fattorusso, C | 1 |
| Catalanotti, B | 1 |
| Giorgi, G | 1 |
| Cagnotto, A | 1 |
| Goegan, M | 1 |
| Mennini, T | 1 |
| Minetti, P | 1 |
| Di Cesare, MA | 1 |
| Mastroianni, D | 1 |
| Scafetta, N | 1 |
| Galletti, B | 1 |
| Stasi, MA | 1 |
| Castorina, M | 1 |
| Pacifici, L | 1 |
| Ghirardi, O | 1 |
| Tinti, O | 1 |
| Carminati, P | 1 |
| Keller, HH | 1 |
| Schaffner, R | 1 |
| Haefely, W | 1 |
| Matsui, Y | 1 |
| Kamioka, T | 1 |
| Massotti, M | 2 |
| Longo, VG | 1 |
| Algeri, S | 2 |
| Brunello, N | 1 |
| Calderini, G | 1 |
| Consolazione, A | 1 |
| Kaakkola, S | 2 |
| Ahtee, L | 8 |
| Berney, S | 1 |
| Hornykiewicz, O | 2 |
| Zharkovskiĭ, AM | 1 |
| Allikmets, LKh | 1 |
| Otter, MIa | 1 |
| Waldmeier, PC | 1 |
| Delini-Stula, AA | 1 |
| Fuenmayor, LD | 1 |
| Vogt, M | 1 |
| Kääriäinen, I | 4 |
| Van Loon, GR | 1 |
| De Souza, EB | 1 |
| Kim, C | 1 |
| Post, RM | 1 |
| Kopanda, RT | 1 |
| Black, KE | 1 |
| Freye, E | 1 |
| Kuschinsky, K | 2 |
| Setler, P | 1 |
| Sarau, H | 1 |
| McKenzie, G | 1 |
| Kääriäinen, K | 1 |
| Vikberg, P | 1 |
| Shore, PA | 1 |
| Dorris, RL | 1 |
| Kaneko, M | 1 |
| Sato, K | 1 |
| Horikoshi, R | 1 |
| Yaginuma, M | 1 |
| Yaginuma, N | 1 |
| Shiragata, M | 1 |
| Kumashiro, H | 1 |
| Castelló, ME | 1 |
| Bolioli, B | 1 |
| Dajas, F | 1 |
| Essig, EC | 1 |
| Jolicoeur, FB | 1 |
| Rivest, R | 1 |
| St-Pierre, S | 1 |
| Drumheller, A | 1 |
| Lannes, B | 1 |
| Micheletti, G | 1 |
| Warter, JM | 1 |
| Kempf, E | 1 |
| Di Scala, G | 1 |
| Masuda, Y | 1 |
| Murai, S | 1 |
| Saito, H | 1 |
| Abe, E | 1 |
| Fujiwara, H | 1 |
| Kohori, I | 1 |
| Itoh, T | 1 |
| Chipkin, RE | 1 |
| Iorio, LC | 1 |
| Coffin, VL | 1 |
| McQuade, RD | 1 |
| Berger, JG | 1 |
| Barnett, A | 1 |
| Campbell, W | 1 |
| Clark, MS | 1 |
| Mitchell, PJ | 1 |
| Needham, PL | 1 |
| Semple, JM | 1 |
| de Graaf, CJ | 1 |
| Korf, J | 1 |
| Olgiati, VR | 1 |
| Stramentinoli, G | 1 |
| Hillegaart, V | 2 |
| Ahlenius, S | 2 |
| Magnusson, O | 2 |
| Fowler, CJ | 2 |
| Thorell, G | 1 |
| Aizenstein, ML | 1 |
| Scavone, C | 1 |
| Steinschreiber, S | 1 |
| de-Lucia, R | 1 |
| Coyle, S | 1 |
| Napier, TC | 1 |
| Breese, GR | 1 |
| Bürki, HR | 2 |
| Ashtee, L | 1 |
| Buncombe, G | 1 |
| Stille, G | 2 |
| Lauener, H | 2 |
| Asper, H | 1 |
| Baggiolini, M | 1 |
| Ruch, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ecopipam Treatment of Tourette Syndrome[NCT01244633] | Phase 1/Phase 2 | 18 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| A Safety and Pilot Activity Study of Ecopipam (PSYRX 101) in the Symptomatic Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease[NCT01065558] | Phase 1 | 5 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Yale Global Tic Severity Score is a composite of subject reported severity of motor (range 0-25) and vocal (range 0-25) tics , as well as an impairment score (range 0-50). The outcome we are using is the Total Tic Severity score which is the sum of the motor and vocal tic severity scores (range 0-50). The higher the score on this scale, the more severe the symptoms. A positive drug effect is associated with a decrease from baseline. (NCT01244633)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Ecopipam | 25.3 |
Change in the self-injurious subscale of the Behavior Problems Inventory (BPI). the BPI is a well-validate test to evaluate the frequency and severity of a patient's self-injurious behavior. Values range from 0 to 50, and a low score means few/less severe behaviors (NCT01065558)
Timeframe: Screening visit and end of study (two weeks)
| Intervention | Change in BPI score (Mean) |
|---|---|
| Ecopipam Treated Patients | 22.5 |
This study's primary outcome is the safety of ecopipam in Lesch-Nyhan patients as measured by standard clinical laboratory tests. The patients will also be observed and questioned about other side effects, such as whether they feel more or less tired.Standard clinical laboratory tests for liver, kidney and blood function were conducted. The normal ranges for each of these tests were different and are too numerous to be individually listed here. However, if any individual value were to be either three-times greater or lesser than the upper or the lower limit of the test, then that value was considered to have been changed. (NCT01065558)
Timeframe: Two weeks
| Intervention | Participants (Number) |
|---|---|
| Ecopipam Treated Patients | 0 |
1 review available for homovanillic acid and Anochlesia
| Article | Year |
|---|---|
Effect of enkephalins on catecholamine metabolism in rat CNS.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenylyl Cyclases; Analgesics; Animals; Brain; Catalepsy; Catecholam | 1978 |
64 other studies available for homovanillic acid and Anochlesia
| Article | Year |
|---|---|
GPR55: A therapeutic target for Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson | 2017 |
Exercise Improves Cognitive Impairment and Dopamine Metabolism in MPTP-Treated Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Catale | 2016 |
Effect of adenosine A(2A) receptor antagonists on L-DOPA-induced hydroxyl radical formation in rat striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Area Under Curve; Benser | 2009 |
Protective effects of aqueous fruit extract from Sea Buckthorn (Hippophae rhamnoides L. Spp. Turkestanica) on haloperidol-induced orofacial dyskinesia and neuronal alterations in the striatum.
Topics: Administration, Oral; Animals; Catalepsy; Dopamine; Exploratory Behavior; Fruit; Haloperidol; Hippop | 2010 |
Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Behavior, Animal; Benzylamines; Cataleps | 2003 |
Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Basal | 2004 |
Effect of neuroleptic drugs on striatal dopamine release and metabolism in the awake rat studied by intracerebral dialysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Dialysis; | 1984 |
Central effects of angiotensin II, its fragment and analogues.
Topics: Angiotensin II; Animals; Apomorphine; Behavior, Animal; Brain; Catalepsy; Catecholamines; Haloperido | 1984 |
A comparison between some biochemical and behavioural effects produced by neuroleptics.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Brain Chemistry; Catalepsy; Dop | 1981 |
Changes in catalepsy and receptor sensitivity following chronic neuroleptic treatment.
Topics: Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Drug Tolerance; Homovanillic Acid; Humans | 1981 |
Synthesis and pharmacological study of the thiophene analogue of taclamine, QM-7184, a new neuroleptic drug with potent alpha-adrenoceptor blocking activity.
Topics: Adrenergic alpha-Antagonists; Animals; Anticonvulsants; Antipsychotic Agents; Benzothiadiazines; Bra | 1983 |
[Differentiation between catalepsies induced by l-tetrahydropalmatine and by haloperidol and morphine (author's transl)].
Topics: Animals; Berberine Alkaloids; Brain Chemistry; Catalepsy; Dopamine; Female; Haloperidol; Homovanilli | 1981 |
Effect of muscimol, a central GABA receptor agonist, on the catalepsy, striatal homovanillic acid increase, and analgesia induced by pilocarpine in rats.
Topics: Analgesics; Animals; Catalepsy; Corpus Striatum; Drug Interactions; Homovanillic Acid; Humans; Male; | 1981 |
Dopamine metabolites and catalepsy after lithium and haloperidol.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Catalepsy; Dopamine; Haloperidol; Homovanillic Acid; | 1982 |
Dopamine increase in the prefrontal cortex correlates with reversal of haloperidol-induced catalepsy in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Catalepsy; Caudate Nucleus; Chromatography, High Pressure L | 1994 |
Nicotine potentiation of haloperidol-induced catalepsy: striatal mechanisms.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Catalepsy; Chromatography, High Pressure | 1993 |
Prevention by (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol.
Topics: 3,4-Dihydroxyphenylacetic Acid; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; C | 1996 |
Duration of catalepsy correlates with increased intrastriatal sulpiride.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Catalepsy; Dopamine; Dopamine | 1997 |
Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 2000 |
Antidopaminergic effects of 1,2,3,4-tetrahydroisoquinoline and salsolinol.
Topics: Animals; Antiparkinson Agents; Apomorphine; Binding, Competitive; Brain Chemistry; Catalepsy; Dopami | 2000 |
Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Catalepsy; C | 2002 |
Interaction of benzodiazepines with neuroleptics at central dopamine neurons.
Topics: Aminooxyacetic Acid; Animals; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Brain; Cat | 1976 |
Cataleptic and anticataleptic effects of muscimol and gabaculine injected into globus pallidus and substantia nigra, and interactions with haloperidol or benzodiazepines.
Topics: 4-Aminobutyrate Transaminase; Animals; Anti-Anxiety Agents; Benzodiazepines; Catalepsy; Corpus Stria | 1978 |
Role of the dopaminergic system in the cataleptogenic action of bulbocapnine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aporphines; Brain Chemistry; Catalepsy; Dopamine; Homovanil | 1979 |
Effect of muscarinic cholinergic drugs on morphine-induced catalepsy, antinociception and changes in brain dopamine metabolism.
Topics: Analgesia; Animals; Body Temperature; Brain; Catalepsy; Corpus Striatum; Dopamine; Drug Interactions | 1977 |
Involvement of striatal dopamine, homovanillic acid and 3,4-dihydroxyphenylacetic acid in the hypothermia and catalepsy induced by haloperidol.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Body Temperature; Catalepsy; Corpus Stria | 1977 |
Effect of mecamylamine on the fate of dopamine in striatal and mesolimbic areas of rat brain; interaction with morphine and haloperidol.
Topics: Animals; Catalepsy; Corpus Striatum; Dopamine; Drug Interactions; Haloperidol; Homovanillic Acid; Hu | 1978 |
The effect of beta-endorphin and met-enkephalin on striatin dopamine metabolism and catalepsy: comparison with morphine.
Topics: Animals; Catalepsy; Corpus Striatum; Dose-Response Relationship, Drug; Endorphins; Enkephalins; Homo | 1977 |
[Relationship of the homovanillic acid content in the rat brain after the administration of a neuroleptic and the degree of dopamine receptor sensitivity to an agonist].
Topics: Animals; Apomorphine; Brain; Catalepsy; Haloperidol; Homovanillic Acid; Humans; Male; Phenylacetates | 1979 |
Serotonin--dopamine interactions in the nigrostriatal system.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Catalepsy; Corpus Striatum; Dopamine; Drug Int | 1979 |
Production of catalepsy and depletion of brain monoamines by a butyrophenone derivative.
Topics: Animals; Biogenic Amines; Body Temperature; Brain Chemistry; Butyrophenones; Catalepsy; Corpus Stria | 1979 |
Effects of GABAergic drugs on the catalepsy, striatal homovanillic acid increase and antinociception caused by pilocarpine in rats.
Topics: Acetates; Aminobutyrates; Aminooxyacetic Acid; Animals; Baclofen; Brain; Catalepsy; Corpus Striatum; | 1977 |
Alterations in brain dopamine and serotonin metabolism during the development of tolerance to human beta-endorphin in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analgesics; Animals; Body Temperature; Brain; Catalepsy; Dopamine; D | 1978 |
Progressive effects of cocaine on behavior and central amine metabolism in rhesus monkeys: relationship to kindling and psychosis.
Topics: Animals; Behavior, Animal; Catalepsy; Cocaine; Female; Haplorhini; Homovanillic Acid; Humans; Hydrox | 1976 |
Effects of fentanyl and droperidol on the dopamine metabolism of the rat striatum.
Topics: Animals; Catalepsy; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Droperidol; Fentany | 1976 |
Differential attenuation of some effects of haloperidol in rats given scopolamine.
Topics: Amphetamine; Animals; Avoidance Learning; Catalepsy; Corpus Striatum; Dose-Response Relationship, Dr | 1976 |
Effects of aminooxyacetic acid and baclofen on the catalepsy and on the increase of mesolimbic and striatal dopamine turnover induced by haloperidol in rats.
Topics: Acetates; Aminobutyrates; Aminooxyacetic Acid; Animals; Baclofen; Brain Chemistry; Catalepsy; Corpus | 1976 |
Effects of aminooxyacetic acid and baclofen on catalepsy, striatal homovanillic acid increase and antinociception caused by methadone in rats.
Topics: Acetates; Aminobutyrates; Aminooxyacetic Acid; Analgesia; Animals; Baclofen; Catalepsy; Corpus Stria | 1976 |
On a prime role for newly synthesized dopamine in striatal function.
Topics: Animals; Catalepsy; Corpus Striatum; Dopamine; Drug Synergism; Female; Haloperidol; Homovanillic Aci | 1975 |
Effect of drugs on metoclopramide-induced catalepsy and increase in striatal homovanillic acid content.
Topics: Animals; Brain Chemistry; Catalepsy; Corpus Striatum; Dopamine; Female; Homovanillic Acid; Humans; M | 1975 |
Inhibition by apomorphine of the metoclopramide-induced catalepsy and increase in striatal homovanillic acid content.
Topics: Animals; Apomorphine; Body Temperature; Brain; Catalepsy; Corpus Striatum; Dopamine; Female; Homovan | 1975 |
Effect of haloperidol on cyclic AMP and inositol trisphosphate in rat striatum in vivo.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Catalepsy; Corpus Striatum; Cyclic AMP; Dopamine; Haloperid | 1992 |
Catalepsy induced by striatal acetylcholinesterase inhibition with fasciculin in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Atropine; Catalepsy; Cholinesterase Inhibitors; Corpus Stri | 1992 |
Influence of acute and chronic haloperidol treatment on dopamine metabolism in the rat caudate-putamen, prefrontal cortex and amygdala.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amygdala; Animals; Behavior, Animal; Brain Chemistry; Catalepsy; Cau | 1991 |
Antiparkinson-like effects of neurotensin in 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Behavior, Animal; Brain Chemistry; Ca | 1991 |
Behavioural, pharmacological and biochemical effects of acute and chronic administration of ketamine in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Catalepsy; | 1991 |
The enhancement of the hypomotility induced by small doses of haloperidol in the phase of dopaminergic supersensitivity in mice.
Topics: Animals; Apomorphine; Catalepsy; Cerebral Cortex; Corpus Striatum; Dopamine; Haloperidol; Homovanill | 1991 |
Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Avoid | 1988 |
Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Avoid | 1988 |
Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Avoid | 1988 |
Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Avoid | 1988 |
BRL 20596, a novel anilide with central dopamine antagonist activity.
Topics: Animals; Apomorphine; Avoidance Learning; Behavior, Animal; Brain Chemistry; Catalepsy; Dextroamphet | 1986 |
Conditional tolerance to haloperidol-induced catalepsy is not caused by striatal dopamine receptor supersensitivity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholine; Animals; Catalepsy; Corpus Striatum; Drug Tolerance; | 1986 |
Biochemical and behavioural indices of striatal dopaminergic activity after 6-methyltetrahydropterin.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Catalepsy; Chromatography, High Pressure | 1987 |
Repeated testing of rats markedly enhances the duration of effects induced by haloperidol on treadmill locomotion, catalepsy, and a conditioned avoidance response.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Avoidance Learning; Catalepsy; Conditioning, Classical; Cor | 1987 |
Suppression of exploratory locomotor activity and increase in dopamine turnover following the local application of cis-flupenthixol into limbic projection areas of the rat striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Catalepsy; Corpus Striatum; Dopamine; Exploratory Behavior; | 1987 |
Differential changes in dopaminergic receptor sensitivity induced by agonist drugs.
Topics: Animals; Apomorphine; Benserazide; Brain Chemistry; Catalepsy; Drug Therapy, Combination; Haloperido | 1985 |
Ontogeny of tolerance to haloperidol: behavioral and biochemical measures.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Brain Chemistry; Catalepsy; Corpus Striatum; D | 1985 |
[Metabolism of dopamine and norepinephrine in rat brain after acute and chronic administration of haloperidol, loxapine and clozapine].
Topics: Animals; Apomorphine; Azepines; Brain; Catalepsy; Chlorides; Corpus Striatum; Dopamine; Drug Evaluat | 1974 |
Catalepsy and stereotyped behaviour in rats treated chronically with methadone: relation to brain homovanillic acid content.
Topics: Animals; Behavior, Animal; Brain Chemistry; Catalepsy; Homovanillic Acid; Humans; Male; Methadone; P | 1973 |
The role of dopamine in pilocarpine-induced catalepsy.
Topics: Animals; Apomorphine; Atropine; Behavior, Animal; Body Temperature; Brain Chemistry; Catalepsy; Corp | 1974 |
Metoclopramide induces catalepsy and increases striatal homovanillic acid content in mice.
Topics: Animals; Body Temperature; Catalepsy; Chemoreceptor Cells; Corpus Striatum; Dose-Response Relationsh | 1974 |
[Effect of neuroleptic agents in the chronic pharmacological experiment].
Topics: Animals; Apomorphine; Behavior, Animal; Catalepsy; Corpus Striatum; Dibenzoxazepines; Drug Tolerance | 1974 |
Effects of morphine on striatal dopamine metabolism: possible mechanism of its opposite effect on locomotor activity in rats and mice.
Topics: Animals; Apomorphine; Brain Chemistry; Catalepsy; Catechols; Caudate Nucleus; Chlorpromazine; Clonid | 1974 |
The effect of narcotic analgesics on the homovanillic acid content of rat nucleus caudatus.
Topics: Analgesics; Animals; Behavior, Animal; Catalepsy; Caudate Nucleus; Codeine; Cyclazocine; Homovanilli | 1973 |
Tolerance phenomena with neuroleptics catalepsy, apomorphine stereotypies and striatal dopamine metabolism in the rat after single and repeated administration of loxapine and haloperidol.
Topics: Animals; Apomorphine; Basal Ganglia; Catalepsy; Corpus Striatum; Dibenzoxazepines; Dopamine; Drug To | 1973 |
Catalepsy and stereotypies in rats treated with methadone; relation to striatal dopamine.
Topics: Animals; Behavior, Animal; Body Temperature; Body Weight; Catalepsy; Corpus Striatum; Dopamine; Dose | 1974 |